A study to assess the safety and tolerability of nebulized PC945 for prophylaxis or pre-emptive therapy against pulmonary aspergillosis in lung transplant recipients.

Brief description of study

The purpose of this study is to learn about how safe and effective a new investigational drug, PC945, can be. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). PC945 is an inhaled drug being studied for the prevention of a common fungus found in the air, Aspergillus, from causing disease in the lungs or airways.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
pulmonary aspergillosis,lung transplant
Age: Between 18 Years - 99 Years
Gender: All

Male and Female, Age 18 or older, received either a single or double lung transplant

Updated on 09 Mar 2024. Study ID: 850194

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).